THE TUBER EXTRACT OF PUERARIA TUBEROSA LINN. COMPETITIVELY INHIBITS DPP-IV ACTIVITY IN NORMOGLYCEMIC RATS
Objective: The main objective of this research was to explore the effect of the polar fraction of tubers of Pueraria tuberosa (PTWE) on DPP-IV activity.
Methods: The comparison of in vitro inhibitory potential between commercially available Galvus (Vildagliptin) and PTWE was determined by measuring percent inhibition and IC50. The enzyme kinetics were also done to reveal the nature of inhibition. In vivo study was done via the glucose tolerance test and by the measurement of increased plasma GLP-1 concentration and DPP-IV activity after glucose load.
Results: PTWE has given the IC50 value of 17.4 mg/ml and was found to be a competitive inhibitor having the Ki value of 13.11 mg/ml. Plasma GLP-1 concentration was increased and DPP-IV activity was decreased after 60 minutes of glucose load in PTWE treated rats as compared to control rats. Overall PTWE was found to be less potential DPP-IV inhibitor than Galvus.
Conclusion: These findings suggest that antidiabetic effect of PTWE could be because of its role in DPP-IV inhibition.
2. Cani PD, Lecourt E, Dewulf EM, Sohet FM, Pachikian BD, Naslain D, Backer FD, et al. Gut microbiota fermentation of prebiotics increases satietogenic and incretin gut peptide production with consequences for appetite sensation and glucose response after a meal. Am J Clin Nutr 2009;90:1236-43.
3. Diakogiannaki E, Gribble FM, Reimann F. Nutrient detection by incretin hormone secreting cells. Physiol Behav 2012:106:387-93.
4. Wu T, Rayner CK, Jones K, Horowitz M. Dietary effects on incretin hormone secretion. Vitam Horm 2010;84:81-110.
5. Davis JA, Singh S, Sethi S, Roy S, Mittra S, Rayasam G, et al. Nature of action of Sitagliptin, the dipeptidyl peptidase-IV inhibitor in diabetic animals. Indian J Pharmacol 2010;42:229-33.
6. Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol: Endocrinol Metab 2004;287:E199-E206.
7. Chakrabarti R, Singh B, Narendra P, Varghese N, Vanchhawng L, H Shihabudeen MS, et al. Dipeptidyl peptidase-IV inhibitory activity of berberis aristata. J Nat Prod 2011;4:158-63.
8. Thornberry NA, Gallwitz B. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). Best Practice Res: Clin Endocrinol Metab 2009;23:479-86.
9. Wang A, Dorso C, Kopcho L, Locke G, Langish R, Harstad E, et al. Potency, selectivity and prolonged binding of saxagliptin to DPP4:maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor. BMC Pharmacol 2012;12:2.
10. Ugleholdt R, Zhu X, Deacon CF, Orskov C, Steiner DF, Holst JJ. Impaired intestinal proglucagon processing in mice lacking prohormone convertase 1. Endocrinology 2004;145:1349-55.
11. Richards MP, McMurtry JP. Expression of proglucagon and proglucagon-derived peptide hormone receptor genes in the chicken. Gen Comp Endocrinol 2008;156:323-38.
12. Baggio LL, Drucker DJ. Biology of Incretins: GLP-1 and GIP. Gastroenterology 2007;132:2131-57.
13. Seino Y, Fukushima M, Yabe D. GIP and GLP-1, the two incretin hormones: Similarities and differences. J Diabetes Invest 2010;1:8-23.
14. Edholm T, Degerblad M, Gryback P, Hilsted L, Holst JJ, Jacobsson H, et al. Differential incretin effects of GIP and GLP-1 on gastric emptying, appetite, and insulin-glucose homeostasis. Neurogastroenterol Motil 2010;22:1191-e315.
15. Bachhawat A, Shihabudeen MS, Thirumurugan K. Screening of fifteen indian ayurvedic plants for alpha-glucosidase inhibitory activity and enzyme kinetics. Int J Pharm Pharm Sci 2011;3:267-74.
16. Omar B, AhrÃ©n B. Pleiotropic mechanisms for the glucose-lowering action of DPP-4 inhibitors. Diabetes 2014;63:2196-2202.
17. Davis JA, Kumar PS, Singh S, Surender A, Roy S, Khanna V, et al. Biological evaluation of RBx-0128, a potent and selective dipeptidyl peptidase-IV inhibitor in type 2 diabetes genetic model. Indian J Pharmacol 2012;44:759-64.
18. Yogisha S, Raveesha KA. Dipepidyl peptidase IV inhibitory activity of Mangifera indica. J Nat Prod 2010;3:76-9.
19. Pandey N, Tripathi YB. Antioxidant activity of tuberosin isolated from Pueraria tuberosa Linn. J Inflammation 2010;7:47.
20. Pandey N, Yadav D, Pandey V, Tripathi YB. Anti-inflammatory effect of Pueraria tuberosa extracts through improvement in activity of red blood cell anti-oxidant enzymes. Ayu 2013;34:297-301.
21. Tripathi AK, Kohli S. Anti-Diabetic activity and phytochemical screening of crude extracts of Pueraria Tuberosa DC. (Fabaceae) grown in india on STZ-induced diabetic rats. Asian J Med Pharm 2013;3:66-73.
22. Maji AK, Pandit S, Banerji P, Banerjee D. Pueraria tuberosa: a review on its phytochemical and therapeutic potential. Nat Prod Res 2014;28:2111â€“27.
23. Wootten D, Simms J, Koole C, Woodman OL, Summers RJ, Christopoulos A, et al. Modulation of the glucagon-like peptide-1 receptor signaling by naturally occurring and synthetic flavonoids. J Pharm Exp Ther 2011;336:540â€“50.
24. Fan J, Johnson MH, Lila MA, Yousef G, de Mejia EG. Berry and Citrus Phenolic Compounds Inhibit Dipeptidyl Peptidase IV: Implications in Diabetes Management. Evidence-Based Complementary Altern Med 2013. doi.org/10.1155/2013/ 479505. [Article in Press]
25. GonzÃ¡lez-AbuÃn N, MartÃnez-Micaelo N, Blay M, Pujadas G, Garcia-VallvÃ© S, Pinent M, et al. Grape seed-derived procyanidins decrease dipeptidyl-peptidase 4 activity and expression. J Agric Food Chem 2012;60:9055-61.
26. Parmar HS, Jain P, Chauhan DS, Bhinchar MK, Munjal V, Yusuf M, et al. DPP-IV inhibitory potential of naringin: an in silico, in vitro and in vivo study. Diabetes Res Clin Pract 2012;97:105-11.